Tafenoquine
| Clinical data | |
|---|---|
| Pronunciation | ta fen' oh kwin |
| Trade names | Krintafel, Arakoda, others |
| Other names | Etaquine, WR 238605, SB-252263 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618050 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | Antimalarial |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| NIAID ChemDB | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C24H28F3N3O3 |
| Molar mass | 463.501 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (what is this?) (verify) | |
Tafenoquine, sold under the brand name Krintafel among others, is a medication used to prevent and to treat malaria. With respect to acute malaria, it is used together with other medications to prevent relapse by Plasmodium vivax. It may be used to prevent all types of malaria. It is taken by mouth.
Common side effects include vomiting, headache, and dizziness. Other side effects may include methemoglobinemia, trouble sleeping, and anaphylaxis. In people with G6PD deficiency, red blood cell breakdown may occur. Use in pregnancy is not recommended. Tafenoquine is in the 8-aminoquinoline family of medications. The mechanism of action is unclear but it is effective both in the liver and bloodstream. A possible mechanism of action and other novel perspectives have been published.
Tafenoquine was approved for medical use in Australia and in the United States in 2018. Tafenoquine is related to primaquine.